SCHEMBL84003

SCHEMBL84003

CC(C)c1ccnc(NC2CCN(S(=O)(=O)C3CC3)CC2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 8/20 0.49
CCND1 P24385 10/20 0.45
CDK2 P24941 10/20 0.45
CDK6 Q00534 9/20 0.45
CCNE1 P24864 8/20 0.45
CHUK O15111 1/20 0.44
MAPK8 P45983 1/20 0.44
MAPK9 P45984 1/20 0.44
MAPK10 P53779 1/20 0.44
MAPK11 Q15759 1/20 0.44
MAPK14 Q16539 1/20 0.44
CDK4 P11802 6/20 0.44
CCNT1 O60563 3/20 0.44
CDK9 P50750 3/20 0.44
CDK1 P06493 3/20 0.43
CCNB1 P14635 3/20 0.43
CCND3 P30281 3/20 0.43
CCNA2 P20248 2/20 0.43
CCNA1 P78396 2/20 0.43
CDK7 P50613 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL84374 0.86 HRH4 (0.40) IKBKBCCND1CDK2CDK6CCNE1
SCHEMBL84453 0.84 IKBKB (0.54) IKBKBCCND1CDK2CDK6CCNE1
SCHEMBL91448 0.84 IKBKB (0.52) IKBKBCCND1CDK2CDK6CCNE1
SCHEMBL83995 0.81 CDK4 (0.47) IKBKBCCND1CDK2CDK6CCNE1
SCHEMBL84414 0.79 CDK1 (0.54) CCND1CDK2CDK6CCNE1MAPK8
SCHEMBL14004978 0.78 MAPK1 (0.57) CCND1CDK2CDK6CCNE1MAPK8
SCHEMBL84078 0.77 CDK1 (0.56) CCND1CDK2CDK6CCNE1MAPK8
SCHEMBL14383122 0.75 CDK4 (0.59) IKBKBCCND1CDK2CDK6CCNE1
SCHEMBL84472 0.75 JAK3 (0.44) CDK2MAPK8MAPK9MAPK10
SCHEMBL29212025 0.73 IKBKB (0.49) IKBKBCCND1CDK2CDK6CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8865732-B2 Heterocyclic compounds and uses thereof NOVARTIS AG (CH) 2014-10-21 US disclosed
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof NOVARTIS AG (CH) 2013-08-15 US disclosed
US-8129394-B2 Heteroaryl-substituted imidazole compounds and uses thereof NOVARTIS AG (CH) 2012-03-06 US disclosed
US-20100003246-A1 Novel heterocyclic compounds and uses therof NOVARTIS AG (CH) 2010-01-07 US disclosed
US-20100003246-A1 Novel heterocyclic compounds and uses therof NOVARTIS AG (CH) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100003246-A1 Novel heterocyclic compounds and uses therof BRAF, ARAF, KRAS IKBKB 541/4885CCND1 747/4885CDK2 20/4885
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof BRAF, RAF1, HRAS IKBKB 345/4885CCND1 919/4885CDK2 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.